JLE

European Journal of Dermatology

MENU

Successful rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as “toxic epidermal necrolysis-like” Volume 32, numéro 6, November-December 2022

Illustrations


  • Figure 1.
Auteurs
1 Department of Dermatology, CHU Bordeaux, F-33000 Bordeaux, Bordeaux, France
2 UMR 1312, Bordeaux institute of Oncology, Team 5 Translational Research on Oncodermatology and Orphean skin diseases, University Bordeaux, F:33000 Bordeaux, France

Immune checkpoint inhibitors (ICIs) lead to cytotoxic Tcell activation and subsequent elimination of cancer cells, often resulting in immune-related adverse events (irAEs). Anti-programmed death 1 (PD1) antibodies cause cutaneous irAEs in up to 40% of patients [1]; most of them are mild and do no impact treatment continuation. A few cases of severe lichenoid-like eruptions, named “toxic epidermal necrolysis (TEN)-like” have been described [2]. We report the first case of anti-PD1 rechallenge after [...]